Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds

Article


Anagani, B., Singh, J., Bassin, J. P., Besra, G. S., Benham, C., Reddy, T. R. K., Cox, J. A. G. and Goyal, M. 2020. Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds. The Cell Surface. 6 (Art. 100041).
AuthorsAnagani, B., Singh, J., Bassin, J. P., Besra, G. S., Benham, C., Reddy, T. R. K., Cox, J. A. G. and Goyal, M.
Abstract

Objectives

The search for new TB drugs has become one of the great challenges for modern medicinal chemistry. An improvement in the outcomes of TB chemotherapy can be achieved by the development of new, shorter, cheap, safe and effective anti-TB regimens.

Methods

Chalcones (1a-1o) were synthesized and evaluated for their antimycobacterial activity against Mycobacterium bovis BCG using growth inhibition assays. Compound 1a was selected as a ‘hit’ compound. The mode of action of compound 1a, was identified by mycolic acid methyl esters (MAMEs) and fatty acid methyl esters (FAMEs) analysis using thin layer chromatography. Dose dependent experiments were conducted by over-expressing components of FAS-II in M. bovis BCG to confirm the target. Ligand binding using intrinsic tryptophan assay and molecular docking were used to further validate the target.

Results

MAMEs and FAMEs analysis showed dose-dependent reduction of MAMEs with the overall abundance of FAMEs suggesting that compound 1a targets mycolic acid biosynthesis. Direct binding of 1a to InhA was observed using an intrinsic tryptophan fluorescence binding assay, and a 2-fold IC₅₀ shift was observed with an InhA overexpressing strain confirming InhA as the cellular target.

Conclusion

The chalcone 1a exhibits potent antimycobacterial activity, displays a good safety profile and is a direct inhibitor of InhA, a key component in mycolic acid synthesis, validating this series for further anti-TB drug development.

JournalThe Cell Surface
Journal citation6 (Art. 100041)
ISSN2468-2330
Year2020
PublisherElsevier
Accepted author manuscript
License
File Access Level
Repository staff only
Publisher's version
License
File Access Level
Anyone
Supplemental file
File Access Level
Anyone
Digital Object Identifier (DOI)doi:10.1016/j.tcsw.2020.100041
Web address (URL)https://doi.org/10.1016/j.tcsw.2020.100041
Publication dates
Online18 May 2020
Publication process dates
Accepted13 May 2020
Deposited19 May 2020
Copyright holder© 2020 The Authors
Permalink -

https://repository.uel.ac.uk/item/88036

Download files

Publisher's version
1-s2.0-S2468233020300086-main-1.pdf
License: CC BY-NC-ND 4.0
File access level: Anyone

Supplemental file
1-s2.0-S2468233020300086-mmc1.docx
File access level: Anyone

  • 20
    total views
  • 11
    total downloads
  • 4
    views this month
  • 3
    downloads this month

Export as

Related outputs

Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration
Ferreira de Almeida Fiuza, Ludmila, Peres, Raiza Brandão, Simões-Silva, Marianne Rocha, da Silva, Patricia Bernardino, Batista, Denise da Gama Jaen, da Silva, Cristiane França, Nefertiti Silva da Gama, Aline, Reddy, T. and Soeiro, Maria de Nazaré Correia 2018. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. European Journal of Medicinal Chemistry. 149, pp. 257-268.
Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents
Peres, Raiza Brandão, Ullah, Asma Inam, de Almeida Fiuza, Ludmila Ferreira, Silva, Patricia Bernardino, Batista, Marcos M., Corcoran, O., Reddy, T. and de Nazaré Correia Soeiro, Maria 2018. Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents. Bioorganic & Medicinal Chemistry Letters. 28 (11), pp. 2018-2022.